Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 14, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$21.5B
sum of reported positions
Reported positions
85
Changes vs prior quarter
178
21 new · 107 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 123 measured positions in 8 quarters, the typical new or larger position finished −4.8 pts against the S&P 500 and 42% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
| Company | Shares | Value | Weight |
|---|---|---|---|
STATE STR SPDR S&P 500 ETF TPUT | 6M | $4.48B | 20.8% |
| 13.6M | $2.54B | 11.8% | |
ELECTRONIC ARTS INC | 7.92M | $1.62B | 7.5% |
| 10.7M | $800M | 3.7% | |
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $19B | $21.5B |
| Positions | 171 | 85 |
| Biggest line | — | STATE STR SPDR S&P 500 ETF T 21% |
| 6.35M |
| $778M |
| 3.6% |
| 13.5M | $733M | 3.4% |
| 8.37M | $667M | 3.1% |
| 2.63M | $628M | 2.9% |
| 5.58M | $619M | 2.9% |
| 2.22M | $602M | 2.8% |
| 1.27M | $528M | 2.5% |
| 1.05M | $526M | 2.4% |
| 14.3M | $506M | 2.4% |
| 1.38M | $459M | 2.1% |
| 10.5M | $449M | 2.1% |
| 1.15M | $435M | 2.0% |
| 1.11M | $415M | 1.9% |
| 12.3M | $384M | 1.8% |
| 4.12M | $378M | 1.8% |
| 830K | $370M | 1.7% |
| 10.2M | $351M | 1.6% |
CRINETICS PHARMACEUTICALS IN | 8.99M | $336M | 1.6% |
| 4.16M | $284M | 1.3% |
| 895K | $241M | 1.1% |
| 5.8M | $224M | 1.0% |
Dyne Therapeutics (DYN)
10K shares in Q1 2026
Syndax Pharmaceuticals (SNDX)
10K shares in Q1 2026
Stoke Therapeutics (STOK)
9,000 shares in Q1 2026
Cummins (CMI)
9,000 shares in Q1 2026
Scholar Rock Holding (SRRK)
7,000 shares in Q1 2026
TERNS PHARMACEUTICALS INC
7,000 shares in Q1 2026
Veracyte, Inc. (VCYT)
7,000 shares in Q1 2026
LivaNova (LIVN)
6,000 shares in Q1 2026
APELLIS PHARMACEUTICALS INC
6,000 shares in Q1 2026
Genedx Holdings (WGS)
5,000 shares in Q1 2026
Ionis Pharmaceuticals (IONS)
4,800 shares in Q1 2026
Axsome Therapeutics (AXSM)
4,000 shares in Q1 2026
Globus Medical (GMED)
4,000 shares in Q1 2026
Celcuity (CELC)
4,000 shares in Q1 2026
Nektar Therapeutics (NKTR)
4,000 shares in Q1 2026
Supernus Pharmaceuticals, Inc. (SUPN)
4,000 shares in Q1 2026
Madrigal Pharmaceuticals (MDGL)
3,319 shares in Q1 2026
Encompass Health (EHC)
3,000 shares in Q1 2026
Mirum Pharmaceuticals (MIRM)
3,000 shares in Q1 2026
Merit Medical Systems, Inc. (MMSI)
3,000 shares in Q1 2026
NUVALENT INC
3,000 shares in Q1 2026
GE HealthCare (GEHC)
3,000 shares in Q1 2026
HealthEquity (HQY)
2,800 shares in Q1 2026
Glaukos Corp. (GKOS)
2,600 shares in Q1 2026
Belite Bio (BLTE)
1,300 shares in Q1 2026
